Yingwu Liu

机构：Tianjin Third Central Hospital, Cell Technology (China), Tianjin International Joint Academy of Biomedicine, Tianjin Fire Research Institute, Tianjin Medical University · ORCID：0000-0003-3084-8638

发表论文 40 篇 · 总被引 311 次 · h-index 9

代表论文

• Relationship between stress hyperglycemia ratio and allcause mortality in critically ill patients: Results from the MIMIC-IV database (2023 · Frontiers in Endocrinology · 被引 76)
• Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial (2020 · Chinese Medical Journal · 被引 46)
• A comparison of the clinical effects and safety between the distal radial artery and the classic radial artery approaches in percutaneous coronary intervention (2020 · Annals of Palliative Medicine · 被引 30)
• Optimization of GRACE Risk Stratification by N-Terminal Pro-B-type Natriuretic Peptide Combined With D-Dimer in Patients With Non-ST-Elevation Myocardial Infarction (2020 · The American Journal of Cardiology · 被引 29)
• Relationship between lncRNA-Ang362 and prognosis of patients with coronary heart disease after percutaneous coronary intervention (2020 · Bioscience Reports · 被引 15)
• Human Plasma Metabolomics Identify 9-cis-retinoic Acid and Dehydrophytosphingosine Levels as Novel biomarkers for Early Ventricular Fibrillation after ST-elevated Myocardial Infarction (2022 · Bioengineered · 被引 12)